Spots Global Cancer Trial Database for A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
Official Title: A Phase I Study of LJM716 in Patients With Squamous Cell Carcinoma of Head and Neck, or HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer
Study ID: NCT01598077
Interventions
Study Description
Brief Summary: This primary purpose of this study is to estimate the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) and preferred dosing schedule of LJM716 given by IV infusion in adult patients with squamous cell carcinoma of head and neck, or esophagus, or HER2 overexpressing metastatic breast cancer or gastric cancer
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Chicago Medical Center University of Chicago (16), Chicago, Illinois, United States
Massachusetts General Hospital SC-5, Boston, Massachusetts, United States
University of Texas/MD Anderson Cancer Center UT MD, Houston, Texas, United States
University of Utah / Huntsman Cancer Institute Huntsman, Salt Lake City, Utah, United States
Novartis Investigative Site, Toronto, Ontario, Canada
Novartis Investigative Site, Seoul, Korea, Korea, Republic of
Novartis Investigative Site, Barcelona, Catalunya, Spain
Novartis Investigative Site, Taipei, , Taiwan
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
